Medpace Holdings, Inc. (MEDP) Income Statement

The sequential slowdown in revenue growth, from 32.0% in Q4 2025 to 17.2% in Q2 2026, suggests that the post-pandemic surge in biotech funding is fading. Despite the deceleration, MEDP continues to grow at a double-digit clip, far exceeding the flat-to-negative growth of ICLR and CRL, indicating sustained market share gains within its SME biotech niche. However, the sub-1.0 book-to-bill ratio of 0.88x in Q1 2026 implies that new awards are not keeping pace with revenue conversion, which may lead to further deceleration in coming quarters if the trend persists.

The 470 basis point decline in gross margin over six quarters appears driven by an increased proportion of reimbursable out-of-pocket expenses, which carry zero margin and can distort the underlying profitability. Despite this, operating margin has held steady around 20-21%, suggesting that MEDP's centralized model and disciplined project selection are effectively managing SG&A and labor costs. The stability in operating margin, even as gross margin compresses, indicates that the company is not losing pricing power but rather experiencing a mix shift that investors should monitor for permanence.

In Q2 2026, operating income grew at a slower pace than revenue, a reversal from prior quarters where operating income scaled faster, highlighting that the company is no longer benefiting from economies of scale. The increase in SG&A, from $48.1M in Q2 2025 to $48.1M in Q2 2026 (flat), but with revenue up 17%, suggests that overhead efficiency is plateauing. This may indicate that MEDP is investing in capacity or facing labor cost inflation that is eroding its historical operating leverage, a trend that warrants close attention.

The significant reduction in SG&A intensity, from 10.4% to 6.8% of revenue, underscores management's disciplined overhead management, likely aided by the centralized hub model. However, the primary cost driver—personnel expenses—is not explicitly broken out, and the recent EPS miss may indicate that labor costs are rising faster than contract escalators. The company's ability to maintain this cost discipline while managing clinical staff turnover will be critical to preserving margins.

The 32.0% growth in Q4 2025 was the highest in the ten-quarter period, but subsequent quarters show a clear deceleration, with Q1 2026 at 26.5% and Q2 2026 at 17.2%. This inflection appears tied to the normalization of biotech funding and a softer demand environment, as evidenced by the sub-1.0 book-to-bill ratio. The lasting impact is that MEDP's growth trajectory is likely to moderate to a more sustainable mid-teens level, which may affect its premium valuation if investors were pricing in continued acceleration.